Reporters.io
Dark Mode
Amy Baxter
Pharma Voice
Profile
Contacts
Recent Articles on Subject
1
Amy Baxter
Pharma Voice
Scientist, inventor, former pediatrician.
Atlanta, Georgia
pain relief
technology
innovation
Rx-to-OTC rule gets pushed back — again
- 9 days ago
Lilly, Novo expand DTC reach of obesity meds after compound win
- 11 days ago
How pharma CEO pay shifted for these 4 companies last year
- about 1 month ago
The kids are alright: How pharma can make inroads with Gen Z
- about 2 months ago
In the crowded cardio space, it’s David vs. Goliath for small biotechs
- about 2 months ago
Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments
- about 2 months ago
RFK Jr. will face these critical tests if confirmed as head of the HHS
- about 2 months ago
Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge
- 2 months ago
What to expect in the sequel to Medicare’s drug price negotiation program
- 3 months ago
Merck is broadening its pipeline as Keytruda’s patent cliff looms
- 3 months ago
FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered
- 3 months ago
3 trial readouts that could shake up the obesity market this year
- 3 months ago
PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?
- 3 months ago
Big Pharma’s new DTC play: partnering with digital health providers
- 4 months ago
A biotech’s race to tackle the most severe hepatitis
- 4 months ago
Oncology, obesity and more: Where pharma R&D is headed in 2025
- 4 months ago
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
- 4 months ago
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
- 4 months ago
With Makary set to face FDA commissioner hearings, how deep do his industry ties run?
- 4 months ago
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
- 4 months ago
Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?
- 4 months ago
What might a Trump administration mean for the Biosecure Act?
- 4 months ago
The first MASH drug could open the door for others — including GLP-1s
- 5 months ago
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
- 5 months ago
What RFK Jr.’s influence could mean for pharma
- 5 months ago
A diabetes drug, twice rejected, stumbles again — but its developer persists
- 5 months ago
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
- 5 months ago
2024 PharmaVoice 100s: Clinical Trial Pros
- 5 months ago
Backlash builds against Novo’s Catalent takeover
- 5 months ago
2024 PharmaVoice 100s: Tech and AI Wizards
- 5 months ago
Where Big Pharma’s campaign cash is flowing in this election
- 5 months ago
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
- 5 months ago
2024 PharmaVoice 100s: Cardiometabolic All-Stars
- 6 months ago
As election day nears, Trump and Harris veer in different directions on pharma
- 6 months ago
How Roche plans to fill a projected $8B sales gap
- 6 months ago
3 FDA approval dates to watch in the year’s final push
- 7 months ago
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
- 7 months ago
FDA adcomm reform talks heat up
- 7 months ago
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
- 8 months ago
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
- 8 months ago
The drugs hit hardest by Medicare price negotiations
- 8 months ago
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
- 8 months ago
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
- 8 months ago
M&A is ready to explode, and that’s good news for pharma layoffs
- 8 months ago
Pharma execs react to final drug price negotiations with Medicare
- 8 months ago
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
- 8 months ago
In a Duchenne market beset by problems, Capricor data marks a bright spot
- 8 months ago
Read to lead: 6 books pharma execs swear by
- 8 months ago
3 Big Pharma cancer drugs facing inflation penalties
- 8 months ago
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
- 8 months ago